The All Wales Medicines Strategy Group (AWMSG) has recommended Trulicity (dulaglutide once weekly injection) for adults with type 2 diabetes mellitus, pharma Eli Lilly has announced.
More than 180,000 people in Wales currently live with diabetes, with a further 70,000 people living with undiagnosed type 2 diabetes. Dulaglutide is licenced for the treatment of adults with type 2 mellitus to improve glyxaemic control in combination with other medication, including insulin, when other options including in conjunction with exercise and diet, have failed to work.
The decision means dulaglutide will now be available for restricted use in Wales as an alternative GLP-1 receptor agonist option in patients with inadequate glycaemic control in the following circumstances:
- After failure, intolerance or where there is contraindication to, standard triple therapy as an alternative to insulin therapy
- In combination with other glucose-lowering medicinal products, but not including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control, in line with current NICE guidance.
Professor Steve Bain, Assistant Medical Director for Research and Development for ABM University Health Board and Clinical Lead for Diabetes Research Network, Wales, said: “The recommendation of Trulicity by the All Wales Medicine Strategy Group is good news as there is now an additional treatment option in Wales to help people better manage their diabetes.
“Living with diabetes is not easy and in practice we see many patients who have not yet been able to obtain optimal glycaemic control and require additional glucose-lowering medication.”